Clinical Trial

Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."

Study acronym: Vivaxin-001
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection
Trial Details
NCT Number NCT07172724
Lead Sponsor Federal University of Minas Gerais
Collaborators: University of Sao Paulo, Financiadora de Estudos e Projetos, Fundação de Amparo à Pesquisa do Estado de São Paulo, INCTV National Institute of Vaccine Science and Technology, The Ministry of Science, Technology and Innovation, Brazil, CT Vacinas - Centro de Tecnologia em Vacinas/Universidade Federal de Minas Gerais
Conditions Malaria Vivax
Enrollment 48 participants
Start Date 2025-09
Primary Completion 2026-03 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-15